BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 30444646)

  • 1. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondria-Targeting Antioxidant Provides Cardioprotection through Regulation of Cytosolic and Mitochondrial Zn
    Olgar Y; Tuncay E; Turan B
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome.
    Ng HY; Kuo WH; Tain YL; Leung FF; Lee WC; Lee CT
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
    Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
    Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
    Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S
    Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
    Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Titin and CK2α are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats.
    Durak A; Bitirim CV; Turan B
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):487-501. PubMed ID: 32377826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
    Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased free Zn
    Olgar Y; Durak A; Tuncay E; Bitirim CV; Ozcinar E; Inan MB; Tokcaer-Keskin Z; Akcali KC; Akar AR; Turan B
    J Cell Mol Med; 2018 Mar; 22(3):1944-1956. PubMed ID: 29333637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
    Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
    Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.